As the Director of Safety Pharmacology for IMAPill Inc, you’…

As the Director of Safety Pharmacology for IMAPill Inc, you’re tasked with evaluating a new drug candidate for CNS evaluation.  A.  In designing your experiments, describe what doses you would select and experimental structure. Please design your experiment, including group number, dosages (no numbers), and rationale for each dosing group. B.  Describe 3 Nervous System Safety Assessments (2 Core, 1 Follow-Up) and how animals would be evaluated in each assessment.    

Terfenadine was withdrawn from the market in 1997. A. Why wa…

Terfenadine was withdrawn from the market in 1997. A. Why was terfenadine withdrawn? Please include 1) a physiologic and 2) metabolic reason in your response. B. What movement (area of study) did terfenadine withdraw initiate? C. Several people a!ected by terfenadine were also found to have ingested a particular food/drink. What cellular scenario did this food/drink create?